Research ExplorerPublicationsImpact of age on outcomes of patients with non-muscle-invasi...

Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C

Standard

Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. / Xylinas, Evanguelos; Kent, Matthew; Dabi, Yohann; Rieken, Malte; Kluth, Luis A; Al Awamlh, Bashir Al Hussein; Ouzaid, Idir; Pycha, Armin; Comploj, Evi; Svatek, Robert S; Lotan, Yair; Karakiewicz, Pierre I; Holmang, Sten; Shariat, Shahrokh F.

In: UROL ONCOL-SEMIN ORI, Vol. 36, No. 3, 03.2018, p. 89.e1-89.e5.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Xylinas, E, Kent, M, Dabi, Y, Rieken, M, Kluth, LA, Al Awamlh, BAH, Ouzaid, I, Pycha, A, Comploj, E, Svatek, RS, Lotan, Y, Karakiewicz, PI, Holmang, S & Shariat, SF 2018, 'Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C', UROL ONCOL-SEMIN ORI, vol. 36, no. 3, pp. 89.e1-89.e5. https://doi.org/10.1016/j.urolonc.2017.11.010

APA

Xylinas, E., Kent, M., Dabi, Y., Rieken, M., Kluth, L. A., Al Awamlh, B. A. H., Ouzaid, I., Pycha, A., Comploj, E., Svatek, R. S., Lotan, Y., Karakiewicz, P. I., Holmang, S., & Shariat, S. F. (2018). Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. UROL ONCOL-SEMIN ORI, 36(3), 89.e1-89.e5. https://doi.org/10.1016/j.urolonc.2017.11.010

Vancouver

Xylinas E, Kent M, Dabi Y, Rieken M, Kluth LA, Al Awamlh BAH et al. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. UROL ONCOL-SEMIN ORI. 2018 Mar;36(3):89.e1-89.e5. https://doi.org/10.1016/j.urolonc.2017.11.010

Bibtex

@article{a33c106246ba4ce9a441f59874b4e746,
title = "Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C",
abstract = "OBJECTIVES: To evaluate whether age affects the clinical benefit afforded by immediate postoperative intravesical instillation of mitomycin C in a contemporary cohort of patients with NMIBC.PATIENTS AND METHODS: A total of 4,258 patients with NMIBC treated with transurethral resection of the bladder with (n = 2,605, 61%) or without (n = 1,652, 39%) one immediate instillation of mitomycin C from 5 institutions (study period: 2000-2007) were included. No patients received adjuvant instillations. A multivariable Cox proportional hazards regression model adjusting for standard clinical and pathological features tested the potential interaction term between age and administration of mitomycin C with regard to disease recurrence.RESULTS: A total of 2,063 patients experienced disease recurrence with a median follow-up of 48 months for those who did not recur. In multivariable Cox regression analysis, immediate postoperative instillation of mitomycin C (HR: 0.62; 95% CI: 0.56-0.68; P<0.0001) and age (HR: 1.04; 95% CI: 1.00-1.09; P = 0.036) were associated with disease recurrence. We observed only slight decreases in recurrence-free survival with age irrespective of treatment administration of mitomycin C or not.CONCLUSION: We confirmed reduced disease recurrence rates associated with 1 immediate postoperative intravesical instillation of mitomycin C in NMIBC patients. The benefit on recurrence-free survival of a postoperative intravesical instillation was preserved across all ages and therefore age by itself should not be taken into consideration when deciding to use it.",
keywords = "Journal Article",
author = "Evanguelos Xylinas and Matthew Kent and Yohann Dabi and Malte Rieken and Kluth, {Luis A} and {Al Awamlh}, {Bashir Al Hussein} and Idir Ouzaid and Armin Pycha and Evi Comploj and Svatek, {Robert S} and Yair Lotan and Karakiewicz, {Pierre I} and Sten Holmang and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2017 Elsevier Inc. All rights reserved.",
year = "2018",
month = mar,
doi = "10.1016/j.urolonc.2017.11.010",
language = "English",
volume = "36",
pages = "89.e1--89.e5",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C

AU - Xylinas, Evanguelos

AU - Kent, Matthew

AU - Dabi, Yohann

AU - Rieken, Malte

AU - Kluth, Luis A

AU - Al Awamlh, Bashir Al Hussein

AU - Ouzaid, Idir

AU - Pycha, Armin

AU - Comploj, Evi

AU - Svatek, Robert S

AU - Lotan, Yair

AU - Karakiewicz, Pierre I

AU - Holmang, Sten

AU - Shariat, Shahrokh F

N1 - Copyright © 2017 Elsevier Inc. All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - OBJECTIVES: To evaluate whether age affects the clinical benefit afforded by immediate postoperative intravesical instillation of mitomycin C in a contemporary cohort of patients with NMIBC.PATIENTS AND METHODS: A total of 4,258 patients with NMIBC treated with transurethral resection of the bladder with (n = 2,605, 61%) or without (n = 1,652, 39%) one immediate instillation of mitomycin C from 5 institutions (study period: 2000-2007) were included. No patients received adjuvant instillations. A multivariable Cox proportional hazards regression model adjusting for standard clinical and pathological features tested the potential interaction term between age and administration of mitomycin C with regard to disease recurrence.RESULTS: A total of 2,063 patients experienced disease recurrence with a median follow-up of 48 months for those who did not recur. In multivariable Cox regression analysis, immediate postoperative instillation of mitomycin C (HR: 0.62; 95% CI: 0.56-0.68; P<0.0001) and age (HR: 1.04; 95% CI: 1.00-1.09; P = 0.036) were associated with disease recurrence. We observed only slight decreases in recurrence-free survival with age irrespective of treatment administration of mitomycin C or not.CONCLUSION: We confirmed reduced disease recurrence rates associated with 1 immediate postoperative intravesical instillation of mitomycin C in NMIBC patients. The benefit on recurrence-free survival of a postoperative intravesical instillation was preserved across all ages and therefore age by itself should not be taken into consideration when deciding to use it.

AB - OBJECTIVES: To evaluate whether age affects the clinical benefit afforded by immediate postoperative intravesical instillation of mitomycin C in a contemporary cohort of patients with NMIBC.PATIENTS AND METHODS: A total of 4,258 patients with NMIBC treated with transurethral resection of the bladder with (n = 2,605, 61%) or without (n = 1,652, 39%) one immediate instillation of mitomycin C from 5 institutions (study period: 2000-2007) were included. No patients received adjuvant instillations. A multivariable Cox proportional hazards regression model adjusting for standard clinical and pathological features tested the potential interaction term between age and administration of mitomycin C with regard to disease recurrence.RESULTS: A total of 2,063 patients experienced disease recurrence with a median follow-up of 48 months for those who did not recur. In multivariable Cox regression analysis, immediate postoperative instillation of mitomycin C (HR: 0.62; 95% CI: 0.56-0.68; P<0.0001) and age (HR: 1.04; 95% CI: 1.00-1.09; P = 0.036) were associated with disease recurrence. We observed only slight decreases in recurrence-free survival with age irrespective of treatment administration of mitomycin C or not.CONCLUSION: We confirmed reduced disease recurrence rates associated with 1 immediate postoperative intravesical instillation of mitomycin C in NMIBC patients. The benefit on recurrence-free survival of a postoperative intravesical instillation was preserved across all ages and therefore age by itself should not be taken into consideration when deciding to use it.

KW - Journal Article

U2 - 10.1016/j.urolonc.2017.11.010

DO - 10.1016/j.urolonc.2017.11.010

M3 - SCORING: Journal article

C2 - 29221642

VL - 36

SP - 89.e1-89.e5

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 3

ER -